Targeting platelet receptors dispensable for hemostasis, but guiding inflammation such as GPVI [44, 48] or key effector receptors of stroke-related inflammation such as TLR4 [32], among others, are worth being pursued clinically based on robust preclinical efficacy and clinical safety data. Here, TLR4 is linked to stroke disorder.